Direct treatment costs for patients with lung cancer from first recurrence to death in France

PharmacoEconomics

Volumn 21, Issue 9, 2003, Pages 671-679

  Braud, Anne Chantal ^a   Lévy Piedbois, Christine ^b   Piedbois, Pascal ^a   Piedbois, Youri ^a   Livartovski, Alain ^c   Le Vu, Béatrice ^c   Trédaniel, Jean ^d   Reboul, François ^e   Brewer, Yvelise ^e   Talbi, Said ^f   Blanchon, François ^f   Paschen, Britta ^g   Durand Zaleski, Isabelle ^h  

^a European Association for Research in Oncology (AERO)   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CURIE   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e INSTITUT SAINTE CATHERINE   (France)

^f Meaux Hospital   (France)

^g MERCK KGAA   (Germany)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; MITOMYCIN; NAVELBINE; TAXANE DERIVATIVE;

ADULT; AGED; AMBULATORY SURGERY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COST OF ILLNESS; DAY CARE; FRANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONEY; NON PROFIT HOSPITAL; PRIORITY JOURNAL; PRIVATE HOSPITAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; TERMINAL CARE;

EID: 0038352089     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321090-00005     Document Type: Article

References (22)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64
2. Ochs JJ, Tester WJ, Cohen MH, et al. "Salvage" radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 1983; 67: 1123-6
3. Veeder MH, Jett JR, Su JQ, et al. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 1992; 70: 2281-7
4. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7
5. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF(G) versus taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) trial [abstract 1145]. Proc Am Soc Clin Oncol 1996; 15: 382
6. Rosell R, Tonato M, Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin Oncol 1998; 25 (4 Suppl. 9): 27-34
7. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14: 2054-60
8. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-70
9. Arbit E, Wronski M, Burt M, et al. The treatment of patients with recurrent brain metastases: a retrospective analysis of 109 patients with non small cell lung cancer. Cancer 1995; 76: 765-73
10. Miller JI, Phillips TW. Neodymium: YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. Ann Thorac Surg 1990; 50: 190-6
11. Wilson GE, Walshaw MJ, Hind CR. Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope. Thorax 1996; 51: 248-52
12. Alexander E, Moriarty TM, Davis RB, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995; 87: 34-40
13. Löffler JS, Kooy HM, Wen PY, et al. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol 1990; 8: 576-82
14. Drummond M, Torrance G, Stoddard G. Economic evaluation of healthcare programmes. Oxford: Oxford University Press, 1996
15. Oken MM, Creech RH, Horton DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55
16. Virgo KS, Naunheim KS, McKirgan LW, et al. Cost of patient follow-up after potentially curative lung cancer treatment. J Thorac Cardiovasc Surg 1996; 112: 356-63
17. Evans WK, Will BP, Berthelot JM, et al. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995; 72: 1270-7
18. Chouaid C, Bassinet L, Fuhrman C, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998; 16: 2700-7
19. Hillner BE, McDonald MK, Desch CE, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol 1998; 16: 1420-4
20. Goodwin PJ, Sheperd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998; 16: 3900-12
21. Oliver E, Killen J, Kiebert G, et al. Killen J, Kiebert G, Hutton J, Hall R, Higgins B, Bourke S, Paschen B. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001; 56: 785-90
22. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80: 215-8